J. Lipid Res. Neurobiology of Lipids (ISSN1683-5506)
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on November 1, 2006

Papers In Press, published online ahead of print July 28, 2006
J. Lipid Res., doi:10.1194/jlr.M600187-JLR200
This Article
Right arrow Full Text (Accepted Manuscript)
Right arrow All Versions of this Article:
M600187-JLR200v1
47/11/2382    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bergamo, P.
Right arrow Articles by Rossi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bergamo, P.
Right arrow Articles by Rossi, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Submitted on May 1, 2006
Revised on July 5, 2006
Accepted on July 27, 2006

Conjugated linoleic acid enhances glutathione synthesis and attenuates pathological signs in MRL/lpr mice

Paolo Bergamo, Diomira Luongo, Francesco Maurano, Giuseppe Mazzarella, Rosita Stefanile, and Mauro Rossi

Istituto di Scienze dell'Alimentazione (ISA), Consiglio Nazionale delle Ricerche (CNR), Avellino 83100

Corresponding Author: p.bergamo{at}isa.cnr.it

Conjugated Linoleic Acid (CLA), a naturally occurring peroxisome proliferator-activated receptor-gamma (PPAR gamma ) ligand, exhibit proapoptotic, immunomodulatory and anti-cancer properties. In this study, we examined the biological effects of CLA administration in the MRL/MpJ-Faslpr (MRL/lpr) mouse, an animal model of systemic lupus erythematosus (SLE). We found that CLA exerted apparently opposed activities in ex vivo experiments, depending on its concentration: 100mu M CLA down-regulated IFNgamma synthesis and cell proliferation of splenocytes, in association with apoptosis induction and decrease of intracellular thiols (GSH + GSSG); 25 mu M CLA instead did not significantly influence cell proliferation, but enhanced the expression of gamma-glutamylcysteine ligase catalytic subunit (GCLC) and intracellular GSH concentration. Interestingly, the anti-proliferative effect at 100 mu M was not inhibited by PPARgamma antagonist GW9662. In vivo, CLA administration drastically reduced SLE signs (splenomegaly, auto-antibodies and cytokine synthesis) a condition paralleled by enhancement of GCLC expression and intracellular GSH content. Moreover, CLA administration significantly down-regulated NFkappa B activity, independently from PPAR gamma activation and apoptosis induction. In conclusion enhanced GSH content and GCLC expression in CLA-treated mice suggests a novel biochemical mechanism underlying its immunomodulatory activity and the beneficial effects on murine SLE signs.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.